Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage – A Meta-Analysis

      Abstract

      Background: The association of lipid lowering therapy and intracerebral hemorrhage risk is controversial. Methods: We performed a cumulative meta-analysis of lipid lowering trials that reported intracerebral hemorrhage. Statin, fibrate, ezetimibe, PCSK9, and CETP trials were included. We explored whether the association of lipid lowering therapy and risk of intracerebral hemorrhage may vary by baseline low-density lipoprotein (LDL) level, mean change in LDL or baseline cardiovascular risk of population. Results: Among 39 trials (287,651 participants), lipid lowering therapy was not associated with a statistically significant increased risk of intracerebral hemorrhage (ICH) in primary and secondary prevention trials combined (odds ratio [OR], 1.12; 95% confidence interval [CI], .98-1.28). Lipid lowering was associated with an increased risk of ICH in secondary prevention trials (OR, 1.18; 95% CI, 1.00-1.38), but not in primary prevention trials (OR, 1.01; 95% CI, .78-1.30), but the test for interaction was not significant (P for interaction = .31). Meta-regression of baseline LDL or difference in LDL reduction between active and control did not explain significant heterogeneity between studies for ICH risk. Of 1000 individuals treated for 1 year for secondary prevention, we estimated 9.17 (95% CI, 5.78-12.66) fewer ischemic strokes and .48 (95% CI, .06-1.02) more ICH, and a net reduction of 8.69 in all stroke per 1000 person-years. Conclusions: The benefits of lipid lowering therapy in prevention of ischemic stroke greatly exceed the risk of ICH. Concern about ICH should not discourage stroke clinicians from prescribing lipid lowering therapy for secondary prevention of ischemic stroke.

      Key Words

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Amarenco P.
        • Labreuche J.
        Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention.
        Lancet Neurol. 2009; 8: 453-463
        • Goldstein L.B.
        Statin therapy should be discontinued in patients with intracerebral hemorrhage.
        Stroke. 2013; 44: 2058-2059
        • Bustamante A.
        • Montaner J.
        Statin therapy should not be discontinued in patients with intracerebral hemorrhage.
        Stroke. 2013; 44: 2060-2061
        • Leppala J.M.
        • Virtamo J.
        • Fogelholm R.
        • et al.
        Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants.
        Stroke. 1999; 30: 2535-2540
        • Ebrahim S.
        • Sung J.
        • Song Y.-M.
        • et al.
        Serum cholesterol, hemorrhagic stroke, ischemic stroke, and myocardial infarction: Korean national health system prospective cohort study.
        BMJ. 2006; 333: 22
        • Iso H.
        • Jacobs D.R.
        • Wentworth D.
        • et al.
        Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial.
        N Engl J Med. 1989; 320: 904-910
        • Reed D.M.
        The paradox of high risk of stroke in populations with low risk of coronary heart disease.
        Am J Epidemiol. 1990; 131: 579-588
        • Yano K.
        • Reed D.M.
        • MacLean C.J.
        Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program.
        Stroke. 1989; 20: 1460-1465
        • Fitzgerald C.
        Use of high-intensity statin in patients with ischemic stroke: observation and opinion of a clinical pharmacist in the inpatient setting.
        Austin J Pharmacol Ther. 2014; 2 (ISSN: 2373-6208): 1059
        • McKinney J.S.
        • Kostis W.J.
        Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials.
        Stroke. 2012; 43: 2149-2156
        • The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
        High-dose atorvastatin after stroke or transient ischemic attack.
        N Engl J Med. 2006; 355: 549-559
        • Mitsios J.V.
        • Papathanasiou A.I.
        • Goudevenos J.A.
        • et al.
        The antiplatelet and antithrombotic actions of statins.
        Curr Pharm Des. 2010; 16: 3808-3814
        • Jun M.
        • Foote C.
        • Lv J.
        • et al.
        Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.
        Lancet. 2010; 375: 1875-1884
        • Moher D.
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        Ann Intern Med. 2009; 151: 264
        • Altman D.G.
        • Bland J.M.
        Interaction revisited: the difference between two estimates.
        BMJ. 2003; 326: 219
        • Viechtbauer W.
        Conducting Meta-Analyses in R with the metafor Package.
        J Stat Softw. 2010; 36 (Available at:) ([cited 2018 May 13])
        • Ito H.
        • Ouchi Y.
        • Ohashi Y.
        • et al.
        A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE).
        J Atheroscler Thromb. 2001; 8: 33-44
        • Wanner C.
        • Krane V.
        • März W.
        • et al.
        Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
        N Engl J Med. 2005; 353: 238-248
        • Yusuf S.
        • Bosch J.
        • Dagenais G.
        • et al.
        Cholesterol lowering in intermediate-risk persons without cardiovascular disease.
        N Engl J Med. 2016; 374: 2021-2031
        • de Lemos J.A.
        • Blazing M.A.
        • Wiviott S.D.
        • et al.
        Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z Trial.
        JAMA. 2004; 292: 1307
        • Holdaas H.
        • Fellström B.
        • Jardine A.G.
        • et al.
        Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo-controlled trial.
        Lancet. 2003; 361: 2024-2031
        • Furberg C.D.
        • Adams H.P.
        • Applegate W.B.
        • et al.
        Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
        Circulation. 1994; 90: 1679-1687
        • GISSI-HF investigators
        Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial.
        Lancet. 2008; 372: 1231-1239
        • Bone H.G.
        • Kiel D.P.
        • Lindsay R.S.
        • et al.
        Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
        J Clin Endocrinol Metab. 2007; 92: 4671-4677
        • Schwartz G.G.
        Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
        JAMA. 2001; 285: 1711
        • Kleemann A.
        Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The Cholesterol Lowering Atherosclerosis PTCA Trial (CLAPT).
        Eur Heart J. 1999; 20: 1393-1406
        • Knopp R.H.
        • d'Emden M.
        • Smilde J.G.
        • et al.
        Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN).
        Diabetes Care. 2006; 29: 1478-1485
        • Pedersen T.R.
        High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
        JAMA. 2005; 294: 2437
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • et al.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group
        Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomized trial.
        Lancet. 2010; 376: 1658-1669
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • et al.
        Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
        N Engl J Med. 2004; 350: 1495-1504
        • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
        Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
        JAMA J Am Med Assoc. 2002; 288: 2998-3007
        • Heart Protection Study Collaborative Group
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Shepherd J.
        • Blauw G.J.
        • Murphy M.B.
        • et al.
        Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial.
        Lancet. 2002; 360: 1623-1630
        • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
        Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
        N Engl J Med. 1998; 339: 1349-1357
        • Sever P.S.
        • Dahlöf B.
        • Poulter N.R.
        • et al.
        Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial.
        The Lancet. 2003; 361: 1149-1158
        • Downs J.R.
        • Clearfield M.
        • Weis S.
        • et al.
        Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS.
        JAMA. 1998; 279: 1615
        • Colhoun H.M.
        • Betteridge D.J.
        • Durrington P.N.
        • et al.
        Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial.
        Lancet. 2004; 364: 685-696
        • Nakamura H.
        • Arakawa K.
        • Itakura H.
        • et al.
        Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial.
        Lancet. 2006; 368: 1155-1163
        • Scandinaviansimvastatinsurvival
        Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344 ([cited 2018 Apr 6] Available from:)
        • GISSI Prevenzione Investigators
        Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge.
        Ital heart J. 2000; 1: 810-820
        • Fellström B.C.
        • Jardine A.G.
        • Schmieder R.E.
        • et al.
        Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
        N Engl J Med. 2009; 360: 1395-1407
        • Kjekshus J.
        • Apetrei E.
        • Barrios V.
        • et al.
        Rosuvastatin in older patients with systolic heart failure.
        N Engl J Med. 2007; 357: 2248-2261
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.H.
        • et al.
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • et al.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • Hosomi N.
        • Nagai Y.
        • Kohriyama T.
        • et al.
        The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study.
        EBioMedicine. 2015; 2: 1071-1078
      1. Treatment with atorvastatin to the national cholesterol educational program goals versus usual care in secondary coronary heart disease prevention. The greek atorvastatin on coronary-heart-disease evaluation (greace) study. Atheroscler Suppl. 2002;3:70.

        • Athyros VG
        • Papageorgiou AA
        • Mercouris BR
        • Athyrou VV
        • Symeonidis AN
        • Basayannis EO
        • Demitriadis DS
        • Kontopoulos AG
        Treatment with atorvastatin to the National Cholesterol Educational Program goal versus' usual'care in secondary coronary heart disease prevention.
        Current medical research and opinion. 2002; 18: 220-228
        • Cannon C.P.
        • Blazing M.A.
        • Giugliano R.P.
        • et al.
        Ezetimibe added to statin therapy after acute coronary syndromes.
        N Engl J Med. 2015; 372: 2387-2397
        • Frick M.H.
        • Elo O.
        • Haapa K.
        • et al.
        Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia.
        N Engl J Med. 1987; 317: 1237-1245
        • THE VETERANS ADMINISTRATION COOPERATIVE STUDY GROUP
        The treatment of cerebrovascular disease with clofibrate: final report of the veterans administration cooperative study of atherosclerosis, neurology section.
        Stroke. 1973; 4: 684-693
        • Baigent C.
        • Landray M.J.
        • Reith C.
        • et al.
        The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial.
        Lancet. 2011; 377: 2181-2192
        • Sabatine M.S.
        • Giugliano R.P.
        • Keech A.C.
        • et al.
        Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N Engl J Med. 2017; 376 (04): 1713-1722
        • Bowman L.
        • Hopewell J.C.
        • et al.
        • HPS3/TIMI55-REVEAL Collaborative Group
        Effects of anacetrapib in patients with atherosclerotic vascular disease.
        N Engl J Med. 2017; 377: 1217-1227
        • Cholesterol Treatment Trialists’ (CTT) Collaboration
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trials.
        Lancet. 2010; 376: 1670-1681
        • Jauch E.C.
        • Saver J.L.
        • Adams H.P.
        • et al.
        Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2013; 44: 870-947